API | pazufloxacin

pazufloxacin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Pazufloxacin (INN) is a fluoroquinolone antibiotic. It is sold in Japan under the brand names Pasil and Pazucross. ^Wikipedia

Chemistry

SMILES: C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
InChIKey: XAGMUUZPGZWTRP-ZETCQYMHSA-N
Mol. Mass: 318.3
ALogP: 1.74 Partition coefficient
ChEMBL Molecule:
pazufloxacin

More Chemistry

Pharmacology

Mechanisms of Action:
- DNA gyrase subunit A (Escherichia coli K-12) ^UniProt
- DNA gyrase subunit B (Escherichia coli K-12) ^UniProt
- DNA topoisomerase 2-alpha (Homo sapiens) ^UniProt
- DNA topoisomerase 2-beta (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

10-(1-aminocyclopropyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7h-pyrido(1,2,3-d,e)(1,4)benzoxazinecarboxylic acid | 7h-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (s)- | pazufloxacin | pazufloxacin mesilate | pazufloxacin mesylate | t 3761 | t-3761

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Conjunctivitis, Bacterial (Phase 3)

Otitis Media (Phase 1)

Otitis Media, Suppurative (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue